Ensuring the right PET scan for the right patient.

Guidelines issued by the National Institute for Clinical Excellence (NICE) in the England and Wales recommend that rapid access to (18)F-deoxyglucose positron emission tomography (FDG-PET) is made available to all appropriate patients with non-small-cell lung cancer (NSCLC). The clinical evidence fo...

Full description

Bibliographic Details
Main Authors: Spiro, S, Buscombe, J, Cook, G, Eisen, T, Gleeson, F, O'Brien, M, Peake, MD, Rowell, N, Seymour, R
Format: Journal article
Language:English
Published: 2008
_version_ 1797062132814053376
author Spiro, S
Buscombe, J
Cook, G
Eisen, T
Gleeson, F
O'Brien, M
Peake, MD
Rowell, N
Seymour, R
author_facet Spiro, S
Buscombe, J
Cook, G
Eisen, T
Gleeson, F
O'Brien, M
Peake, MD
Rowell, N
Seymour, R
author_sort Spiro, S
collection OXFORD
description Guidelines issued by the National Institute for Clinical Excellence (NICE) in the England and Wales recommend that rapid access to (18)F-deoxyglucose positron emission tomography (FDG-PET) is made available to all appropriate patients with non-small-cell lung cancer (NSCLC). The clinical evidence for the benefits of PET scanning in NSCLC is substantial, showing that PET has high accuracy, sensitivity and specificity for disease staging, as well as pre-therapeutic assessment in candidates for surgery and radical radiotherapy. Moreover, PET scanning can provide important information to assist in radiotherapy treatment planning, and has also been shown to correlate with responses to treatment and overall outcomes. If the government cancer waiting time targets are to be met, rapid referral from primary to secondary healthcare is essential, as is early diagnostic referral within secondary and tertiary care for techniques such as PET. Studies are also required to explore new areas in which PET may be of benefit, such as surveillance studies in high-risk patients to allow early diagnosis and optimal treatment, while PET scanning to identify treatment non-responders may help optimise therapy, with benefits both for patients and healthcare resource use. Further studies are needed into other forms of lung cancer, including small-cell lung cancer and mesothelioma. In conclusion, PET scanning has the potential to improve the diagnosis and management of lung cancer for many patients. Further studies and refinement of guidelines and procedures will maximise the benefit of this important technique.
first_indexed 2024-03-06T20:41:12Z
format Journal article
id oxford-uuid:345a40f1-dde9-451f-a4bf-53a42198bbaa
institution University of Oxford
language English
last_indexed 2024-03-06T20:41:12Z
publishDate 2008
record_format dspace
spelling oxford-uuid:345a40f1-dde9-451f-a4bf-53a42198bbaa2022-03-26T13:25:26ZEnsuring the right PET scan for the right patient.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:345a40f1-dde9-451f-a4bf-53a42198bbaaEnglishSymplectic Elements at Oxford2008Spiro, SBuscombe, JCook, GEisen, TGleeson, FO'Brien, MPeake, MDRowell, NSeymour, RGuidelines issued by the National Institute for Clinical Excellence (NICE) in the England and Wales recommend that rapid access to (18)F-deoxyglucose positron emission tomography (FDG-PET) is made available to all appropriate patients with non-small-cell lung cancer (NSCLC). The clinical evidence for the benefits of PET scanning in NSCLC is substantial, showing that PET has high accuracy, sensitivity and specificity for disease staging, as well as pre-therapeutic assessment in candidates for surgery and radical radiotherapy. Moreover, PET scanning can provide important information to assist in radiotherapy treatment planning, and has also been shown to correlate with responses to treatment and overall outcomes. If the government cancer waiting time targets are to be met, rapid referral from primary to secondary healthcare is essential, as is early diagnostic referral within secondary and tertiary care for techniques such as PET. Studies are also required to explore new areas in which PET may be of benefit, such as surveillance studies in high-risk patients to allow early diagnosis and optimal treatment, while PET scanning to identify treatment non-responders may help optimise therapy, with benefits both for patients and healthcare resource use. Further studies are needed into other forms of lung cancer, including small-cell lung cancer and mesothelioma. In conclusion, PET scanning has the potential to improve the diagnosis and management of lung cancer for many patients. Further studies and refinement of guidelines and procedures will maximise the benefit of this important technique.
spellingShingle Spiro, S
Buscombe, J
Cook, G
Eisen, T
Gleeson, F
O'Brien, M
Peake, MD
Rowell, N
Seymour, R
Ensuring the right PET scan for the right patient.
title Ensuring the right PET scan for the right patient.
title_full Ensuring the right PET scan for the right patient.
title_fullStr Ensuring the right PET scan for the right patient.
title_full_unstemmed Ensuring the right PET scan for the right patient.
title_short Ensuring the right PET scan for the right patient.
title_sort ensuring the right pet scan for the right patient
work_keys_str_mv AT spiros ensuringtherightpetscanfortherightpatient
AT buscombej ensuringtherightpetscanfortherightpatient
AT cookg ensuringtherightpetscanfortherightpatient
AT eisent ensuringtherightpetscanfortherightpatient
AT gleesonf ensuringtherightpetscanfortherightpatient
AT obrienm ensuringtherightpetscanfortherightpatient
AT peakemd ensuringtherightpetscanfortherightpatient
AT rowelln ensuringtherightpetscanfortherightpatient
AT seymourr ensuringtherightpetscanfortherightpatient